| Date | Title | Description |
| 19.10.2024 | What exactly is 'moderate drinking'? Here's what the research suggests and how to think about it | Over the past several years, there has been a rise in alcohol-related deaths and a steady wave of news about the health risks of drinking. Calls for people to drink only in moderation have become more urgent. But what, exactly, does that me... |
| 27.09.2024 | Communiqué de presse : Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO | Dupixent est le premier médicament biologique approuvé aux États-Unis pour le traitement de la BPCO Dupixent est indiqué à environ 300 000 adultes aux États-Unis présentant une BPCO inadéquatement contrôlée et un phénotype éosinophilique. L... |
| 27.09.2024 | Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD | Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype Following recent app... |
| 27.09.2024 | Press Release: Dupixent approved in the US as the first-ever biologic medicine for patients with COPD | Dupixent approved in the US as the first-ever biologic medicine for patients with COPD
Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype Following recent app... |
| 26.09.2024 | Tagrisso US approval in unresectable lung cancer | Tagrisso US approval in unresectable lung cancer
Thu, Sep 26, 2024 08:00 CET Report this content
26 September 2024
Tagrisso approved in the US for patients with
unresectable, Stage III EGFR-mutated lung cancer
Based on LAURA Phase III trial... |
| 25.09.2024 | Get To Know Severe Asthma: The Chronic, Life-Threatening Condition Affecting 7-11% Adults In Asian Countries | KUALA LUMPUR, Malaysia, Sept. 25, 2024 /PRNewswire/ -- Asthma is well-known as a common respiratory condition. But did you know that there exists a life-threatening type of the condition called severe asthma, that requires specialised, mult... |
| 23.09.2024 | Fasenra recommended for EU approval in EGPA | Fasenra recommended for EU approval in EGPA
Mon, Sep 23, 2024 08:05 CET Report this content
23 September 2024
Fasenrarecommended for approval in the EU by CHMP for the treatment of
eosinophilic granulomatosis with polyangiitis
New indicatio... |
| 20.09.2024 | Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for trans... | Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
Approval based on positive results from the IMROZ... |
| 20.09.2024 | Communiqué de presse : Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagno... | Approbation du Sarclisa aux États-Unis : premier anti-CD38, en association avec un traitement conventionnel, pour les patients atteints d’un myélome multiple nouvellement diagnostiqué, non éligibles à une transplantation
Approbation fondée ... |
| 20.09.2024 | Press Release: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for trans... | Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant
Approval based on positive results from the IMROZ... |
| 20.09.2024 | Press Release: Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old | Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old Recommendation based on a phase 3 study showing a significantly greater proportion of children on Dupixent achieved histol... |
| 19.09.2024 | Cure HHT's Advocacy Effort, Support Helps NIH-Sponsored PATH Trial Become First Successful, Large-Scale Randomized Trial For HHT | For more than 30 years, Cure HHT has helped to expand the research and medical community focusing on HHT.
Cure HHT plays pivotal role in the NIH-sponsored PATH Trial becoming the first successful, large-scale randomized trial for HHT -- the... |
| 18.09.2024 | FASENRA EGPA US FDA APPROVAL | FASENRA EGPA US FDA APPROVAL
Wed, Sep 18, 2024 08:45 CET Report this content
18 September 2024
Fasenra approved in the US for eosinophilic granulomatosis with polyangiitis
New indication supported by the MANDARA trial which showed nearly 60... |
| 17.09.2024 | Combination Treatment Extends Survival in Advanced Bladder Cancer | Immunotherapy administered before and after chemotherapy along with surgical removal of the bladder improved survival compared to chemotherapy alone in patients with muscle-invasive bladder cancer, according to results of a recent clinical ... |
| 14.09.2024 | Новый анализ крови может выявить риск сердечно-сосудистых заболеваний за несколько лет до симптомов | Новое исследование показывает, что анализ крови на содержание определенных жиров и маркеров воспаления позволяет предвидеть сердечно-сосудистые заболевания (ССЗ) у женщин за несколько лет до появления симптомов, что является значительным ша... |
| 12.09.2024 | Coloplast Altis Injury Lawsuit Filed: Extremity Pain in Focus | Lashema Thomas Case
From Dr. Le Mai Tu's article “Management of Female Stress Urinary Incontinence with Single-incision Mini-sling (Altis): 36 Month Multicenter Outcomes” in Neurourology Urodynamics. 2023; 42: 1722-1732.
Study reveals uniqu... |
| 03.09.2024 | Coloplast Altis Long-Term Outcomes: New Onset Urgency Deserves Attention | Dr. Greg Vigna
The Altis device in this large, long-term study appears to be associated with four-times more urinary urgency than other mid-urethral slings.
There is evidence that urgency has a ‘far greater’ negative effect on a person’s qu... |
| 28.08.2024 | The Opioid Crisis: A Battle with Shadows | The opioid crisis looms large over America. It’s a specter that haunts families, communities, and healthcare systems. The numbers are staggering. Over 100,000 overdose deaths in a single year. A million lives lost in two decades. These figu... |
| 28.08.2024 | Colocación Profiláctica de Malla Miduretral en el Momento de la Histerectomía: Fin de una era Oscura | Dr. Greg Vigna
Debate sobre la práctica de la colocación de malla mediouretral al momento de la histerectomía en mujeres sin antecedentes de incontinencia urinaria de esfuerzo
Hay un riesgo de incontinencia después de una histerectomía simp... |
| 27.08.2024 | Vigna Law Group: Más Malas Noticias para la Malla de Uretra Media Coloplast Altis: Dolor en la Ingle | Dr. Greg Vigna
Las mini-mallas no reducen el dolor en la ingle en comparación con las mallas mid-uretrales de longitud completa
El dispositivo Altis debería tener una bandera. La FDA aún no respalda la seguridad y eficacia de las mini malla... |
| 23.08.2024 | У 25% пациентов, которые находились в коме, обнаружили скрытое сознание | Один из четырех пациентов, которые не проявляют признаков реагирования после перенесенных серьезных травм головного мозга, на самом деле может оставаться в сознании. Новое исследование указывает на то, что пациенты в коме могут осознавать с... |
| 22.08.2024 | Leqembi (lecanemab) authorized for early Alzheimer’s disease in Great Britain | Leqembi (lecanemab) authorized for early Alzheimer’s disease in Great Britain
Thu, Aug 22, 2024 11:05 CET Report this content
Stockholm, Sweden August 22, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today t... |
| 22.08.2024 | GREED TO DO GOOD: The Untold Story of CDC's Disastrous War on Opioids (Amplify Publishing) is OUT TODAY! | BALTIMORE, Aug. 22, 2024 /PRNewswire/ -- When the Centers for Disease Control and Prevention (CDC) announced that overdose deaths had quadrupled in ten years, hitting a record high of 90,000 in 2020, opioid researchers around the country ex... |
| 20.08.2024 | New Horizons in Cancer Treatment: Hope on the Horizon | Cancer is a relentless foe. It creeps into lives, turning the ordinary into the extraordinary struggle. But recent advancements in treatment are changing the narrative. New therapies are emerging, offering hope where there was once despair.... |
| 20.08.2024 | Seguimiento de los Datos del NEJM Sobre la Mini-cinta de una Sola Incisión | Dr. Greg Vigna
Los datos subyacentes compararon las complicaciones de las cintas retropúbicas con las cintas transobturadoras y compararon la mini-cinta Altis con la Bard
El grupo de mini-sling en el estudio ampliamente citado del Dr. Abdel... |
| 19.08.2024 | Advancements in blood cancer treatments expand patient options | Listen to this article
Advancements in blood cancer treatments expand patient options
1 min
New: You can now listen to articles.
This audio is generated by an AI tool.
Every 25 seconds, someone in the world is diagnosed with a blood cancer1... |
| 16.08.2024 | Imfinzi approved in US for resectable lung cancer | Imfinzi approved in US for resectable lung cancer
Fri, Aug 16, 2024 08:00 CET Report this content
16 August 2024
Imfinzi approved in the US for the treatment of resectable
non-small cell lung cancer before and after surgery
Based on AEGEAN ... |
| 15.08.2024 | Text-to-speech brain implant restores ALS patient's voice | A man with amyotrophic lateral sclerosis (ALS) who had lost his ability to speak has been able to communicate with a Blackrock Neurotech text-to-speech brain implant, researchers said in one of two new studies showing the promise of brain-c... |
| 14.08.2024 | Leqembi approved for the treatment of Alzheimer’s disease in the United Arab Emirates | Leqembi approved for the treatment of Alzheimer’s disease in the United Arab Emirates
Wed, Aug 14, 2024 01:00 CET Report this content
Stockholm, Sweden, August 14, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announ... |
| 01.08.2024 | Leqembi revenue more than doubled – totaled JPY 6.3 billion in the second quarter 2024 | Leqembi revenue more than doubled – totaled JPY 6.3 billion in the second quarter 2024
Thu, Aug 01, 2024 12:45 CET Report this content
Stockholm, Sweden, August 1, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today ... |
| 01.08.2024 | ORTHOPAEDIC SURGEON-SCIENTIST DR. FRANK HENN NAMED CHAIR OF THE DEPARTMENT OF ORTHOPAEDICS | BALTIMORE, Aug. 1, 2024 /PRNewswire/ -- University of Maryland School of Medicine (UMSOM) Dean Mark T. Gladwin, MD, announced today that R. Frank Henn, III, MD, Professor of Orthopaedics, who has served as Interim Chair of the Department si... |
| 31.07.2024 | Lecanemab: A Beacon of Hope in the Fight Against Alzheimer’s Disease | In the battle against Alzheimer’s disease, a new warrior has emerged: lecanemab, marketed as LEQEMBI. Recent findings presented at the Alzheimer’s Association International Conference (AAIC) 2024 reveal that this dual-acting antibody is not... |
| 31.07.2024 | Health | Long COVID ties heart disease for health outcomes. Vaccines reduce risk: study | “Data like this (study) will be important for booster recommendations going forward,” Hoft said.
Al-Aly said he saw long COVID in patients who would come to him with COVID symptoms long past the infection’s end. He would hear of ongoing bra... |
| 30.07.2024 | Improving care for patients with acute lymphocytic leukemia | The first time Becky Yu saw the Philadelphia skyline lit up at night was the evening she and her husband, Brian Currie, drove from their home in Delaware to Penn Medicine to begin her treatment for acute lymphocytic leukemia (ALL), a type o... |
| 30.07.2024 | New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI® (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer’s Disease Patients Presented at The Alz... | 51% of No Tau / Low Tau Patients Showed Improved Cognition and Function Over Three Years; Only Lecanemab Has Clinical Data in No Tau / Low Tau Patient Group
Clinical Data and Biomarkers Show Alzheimer’s Disease Does Not Stop Progressing Aft... |
| 30.07.2024 | Long-term lecanemab data show increased patient benefit with maintained safety profile | Long-term lecanemab data show increased patient benefit with maintained safety profile
Tue, Jul 30, 2024 23:00 CET Report this content
Stockholm, Sweden July 30, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today pr... |
| 27.07.2024 | Lecanemab's EU Setback: A Race Against Time for Alzheimer's Treatment | In a world where time is a precious commodity, the recent decision by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has sent ripples of disappointment through the Alzheimer’s community. On ... |
| 27.07.2024 | Lecanemab: A Beacon of Hope in Alzheimer’s Treatment | The Alzheimer’s Association International Conference (AAIC) 2024 is set to unveil groundbreaking data on lecanemab, a drug that could reshape the landscape of Alzheimer’s disease (AD) treatment. As the conference approaches, excitement is p... |
| 26.07.2024 | The Long Shadow of Long COVID and the Medicaid Gap | The pandemic has left a complex legacy. Long COVID and the Medicaid coverage gap are two pressing issues that continue to haunt millions of Americans. Each presents a unique challenge, yet both share a common thread: the struggle for health... |
| 26.07.2024 | ODAC reviewed Imfinzi in resectable lung cancer | ODAC reviewed Imfinzi in resectable lung cancer
Fri, Jul 26, 2024 08:00 CET Report this content
26 July 2024
FDA Advisory Committee reviewed Imfinzi for treatment of resectable non-small cell lung cancer based on AEGEAN Phase III trial resu... |
| 26.07.2024 | Eisai will seek re-examination of CHMP opinion för lecanemab | Eisai will seek re-examination of CHMP opinion för lecanemab
Fri, Jul 26, 2024 13:15 CET Report this content
Stockholm, Sweden July 26, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they will req... |
| 26.07.2024 | CHMP has adopted a negative opinion on lecanemab for the EU | CHMP has adopted a negative opinion on lecanemab for the EU
Fri, Jul 26, 2024 12:40 CET Report this content
Stockholm, Sweden July 26, 2024 – The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) h... |
| 25.07.2024 | The Lingering Shadow of Long COVID: A Global Health Crisis**
** | ** Long COVID is a specter haunting millions. It’s not just a health issue; it’s a societal crisis. Since the onset of the pandemic, this condition has emerged as a significant disability, robbing individuals of their vitality and draining ... |
| 25.07.2024 | Health | Long COVID risk has decreased but remains significant, study finds | “It’s good news,” said Al-Aly, a coauthor of the study. “Long COVID is on the descent. It’s declining and has gone down over the course of the pandemic.”
But it’s still a concern that long COVID rates remain as high as they are, Al-Aly said... |
| 23.07.2024 | Long-term treatment data for lecanemab to be presented at AAIC 2024 | Long-term treatment data for lecanemab to be presented at AAIC 2024
Tue, Jul 23, 2024 08:00 CET Report this content
Stockholm, July 23, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that its partner Eisai will presen... |
| 19.07.2024 | Long COVID has affected millions. Here's what scientists now know. | Ziyad Al-Aly is chief of research and development at VA St. Louis Health Care System and a clinical epidemiologist at Washington University in St. Louis.
Since 2020, the condition known as long COVID-19 has become a widespread disability af... |
| 18.07.2024 | NEJM publishes ALTUVOCT® phase 3 XTEND-Kids results highlighting treatment potential for children with severe haemophilia A | NEJM publishes ALTUVOCT® phase 3 XTEND-Kids results highlighting treatment potential for children with severe haemophilia A
Thu, Jul 18, 2024 08:00 CET Report this content XTEND-Kids is the first assessment of once-weekly ALTUVOCT® prophyla... |
| 17.07.2024 | Press Release: NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A | NEJM publishes ALTUVIIIO XTEND-Kids phase 3 data supporting its potential to transform the treatment landscape for children with severe hemophilia A ALTUVIIIO provides high-sustained factor levels with once-weekly dosing in children under 1... |
| 15.07.2024 | Health | From Dr. Oz to heart valves: A tiny device charted a contentious path through the FDA | The MitraClip story is, in many ways, a cautionary tale about the science, business, and regulation of medical devices.
Manufacturer-sponsored research on the device has long been questioned. In 2013, an outside adviser to the FDA compared ... |
| 15.07.2024 | 16-Year-Old Marathon Swimmer Maya Merhige Successfully Swims the English Channel and Raises More than $100,000 to Fight Cancer | 16-Year-Old Marathon Swimmer Maya Merhige Successfully Swims the English Channel and Raises More than $100,000 to Fight Cancer with Swim Across America.
Berkeley, California, Resident Is Now One of the Youngest in History to Complete the Tr... |
| 15.07.2024 | How Kaiser Permanente is using gen AI to ‘paradoxically’ make care more human again | Join our daily and weekly newsletters for the latest updates and exclusive content on industry-leading AI coverage. Learn More
The implications for AI in healthcare are vast and significant — however, medical facilities and institutions sho... |
| 13.07.2024 | Red wine used to be lauded as good for the heart – how did it lose its health halo? | In a 1991 segment of 60 Minutes, the CBS correspondent Morley Safer asked how it could be that the French enjoyed high-fat foods like pate, butter and triple creme Brie, yet had lower rates of heart disease than people in the United States.... |
| 13.07.2024 | She signed up for a complicated clinical trial. It may cure her lupus. | West Virginia teacher Sierra Butler spent years of her life dealing with symptoms she couldn't connect including fatigue, joint pain and weight loss. In 2020, she lost over 100 pounds — and the ability to walk.
Finally, she got a diagnosis:... |
| 12.07.2024 | Leqembi approved for the treatment of Alzheimer’s disease in Israel | Leqembi approved for the treatment of Alzheimer’s disease in Israel
Fri, Jul 12, 2024 01:30 CET Report this content
Stockholm, Sweden, July 12, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that Leqem... |
| 11.07.2024 | Leqembi approved for the treatment of Alzheimer’s disease in Hong Kong | Leqembi approved for the treatment of Alzheimer’s disease in Hong Kong
Thu, Jul 11, 2024 01:30 CET Report this content
Stockholm, Sweden, July 11, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that th... |
| 10.07.2024 | Health | Mounjaro bests Ozempic for weight loss in first head-to-head comparison of real-world use | The findings were published Monday in JAMA Internal Medicine.
Dr. Matthew Freeby, an endocrinologist and director of the Gonda Diabetes Center at UCLA’s Geffen School of Medicine, said the study results are in line with what he has observed... |
| 05.07.2024 | Is fish oil helpful or harmful for the heart? A lot of studies but the benefits are unclear | In 1970, two Danish researchers travelled to Greenland to investigate a nutritional paradox: The Inuit people living in the region consumed foods very high in fat, yet reportedly had very low rates of heart attacks.
That observation flew in... |
| 03.07.2024 | Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD | Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark phase 3 studies showing Dupixent... |
| 03.07.2024 | Communiqué de presse : Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenne | Dupixent devient le tout premier médicament ciblé pour le traitement de la BPCO approuvé dans l’Union européenne Première approbation au monde de Dupixent pour le traitement de la BPCO non contrôlée de l’adulte avec éosinophilie sanguine él... |
| 03.07.2024 | Press Release: Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD | Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD First-in-world approval of Dupixent for adults with uncontrolled COPD with raised blood eosinophils based on two landmark phase 3 studies showing Dupixent... |
| 02.07.2024 | Как работает эффект плацебо | Многие относятся к эффекту плацебо с большим скептицизмом, будучи уверенными, что от пустышки не может быть эффекта. И я это вполне понимаю, никто не хочет платить деньги за воздух. Но посмотрим на это с научной точки зрения и почему в мире... |
| 28.06.2024 | Leqembi[®] (lecanemab) launched in China | Leqembi[®] (lecanemab) launched in China
Fri, Jun 28, 2024 01:30 CET Report this content
Stockholm, Sweden, June 28, 2024 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced today that Leqembi® (brand name in Ch... |
| 26.06.2024 | Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM | Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM Majority of patients in this age group with eosinophilic esophagitis receiving Dupixent achieved histologic remission, with im... |
| 26.06.2024 | Press Release: Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM | Dupixent positive phase 3 data in children one to 11 years of age with eosinophilic esophagitis published in NEJM Majority of patients in this age group with eosinophilic esophagitis receiving Dupixent achieved histologic remission, with im... |
| 26.06.2024 | Communiqué de presse : Publication dans le NEJM des données positives de phase III du Dupixent dans le traitement de l’œsophagite à éosinophiles de l’enfant âgé de 12 mois à 11 ans | Publication dans le NEJM des données positives de phase III du Dupixent dans le traitement de l’œsophagite à éosinophiles de l’enfant âgé de 12 mois à 11 ans La majorité des patients de cette tranche d’âge traités par Dupixent pour une œsop... |
| 25.06.2024 | Bird flu survived pasteurization of heavily infected milk: study | Listen to the article 4 min
This audio is auto-generated. Please let us know if you have feedback.
In raw milk samples mixed with high levels of the bird flu, small amounts of the virus still remained after going through a standard pasteuri... |
| 24.06.2024 | Ozempic® (semaglutide) injection 1 mg demonstrated reduction in risk of kidney disease-related events in Phase 3 FLOW trial presented at the 84th Scientific Sessions of the American Diabetes Associati... | Semaglutide 1 mg demonstrated a statistically significant and superior reduction of 24% in the risk of kidney disease-related events vs. placebo in adults with type 2 diabetes and chronic kidney disease.
Based on FLOW trial data, Novo Nordi... |
| 20.06.2024 | Keymed Biosciences Announces Safety and Efficacy Results of CM313 for Primary Immune Thrombocytopenia Published in NEJM | CHENGDU, China, June 20, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced that Lei Zhang/Renchi Yang's team from the Institute of Hematology, Chinese Academy of Medical Sciences has recently published a research pa... |
| 20.06.2024 | Doctoring Beyond the Walls of Hospitals Builds Trust and Loyal Patients: How One Doctor Does It and Saves Lives | How One Doctor Does It and Saves Lives
Some might think it impossible to land an article in the New England Journal of Medicine. After all, only 5% of research submissions are accepted each year, and that's worldwide. Dr. Sylvia Owusu-Ansah... |
| 19.06.2024 | Family's genes offer new clue to delaying onset of Alzheimer's disease | Scientists studying a family plagued by early-in-life Alzheimer's found some carry a genetic oddity that delays their initial symptoms by five years.
The finding points to novel ways of fighting the mind-robbing disease — if researchers can... |
| 18.06.2024 | Altis Single-incision Sling: Acute Pain Explained | Dr. Greg Vigna
Altis sling is criticized for causing groin pain and dyspareunia, with concerns over its safety due to its stiffness and buckling after implantation
We believe the Altis sling polypropylene mesh is too stiff and too short and... |
| 17.06.2024 | NIH-Funded Intervention Did Not Impact Opioid-Related Overdose Death Rates Over Evaluation Period | COVID-19 pandemic and increasingly dangerous drug supply among factors that may have contributed to diminished impact of intervention
A data-driven intervention that engaged communities to rapidly deploy evidence-based practices to reduce o... |
| 17.06.2024 | Bird flu virus outlasted pasteurization, study finds | figcaption>span]:font-sans" data-chromatic="ignore">
A small but detectable amount of H5N1 bird flu survived a standard pasteurization method on milk infected with high concentrations of the virus, National Institutes o... |
| 14.06.2024 | Infectious bird flu survived milk pasteurization in lab tests, study finds. Here's what to know. | A "small but detectable quantity" of infectious H5N1 bird flu virus was able to survive a common approach to pasteurizing milk, according to new research co-authored by scientists at the National Institutes of Health.
The findings... |
| 11.06.2024 | Novel Drug May Improve Oxygen Uptake in Hypertrophic Cardiomyopathy | Patients with obstructive hypertrophic cardiomyopathy who received a novel cardiac myosin inhibitor drug demonstrated improved oxygen uptake, according to a recent clinical trial results published in the New England Journal of Medicine.
“It... |
| 10.06.2024 | FDA accepts filing of Leqembi[®] (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s Disease | FDA accepts filing of Leqembi[®] (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer’s Disease
Mon, Jun 10, 2024 01:30 CET Report this content
Stockholm, Sweden, June 10, 2024 – BioArctic AB’s (publ) (Nasdaq... |
| 05.06.2024 | Health | Ozempic may help fight kidney disease, study finds | Drugs with semaglutide work by mimicking a naturally occurring hormone that causes the pancreas to release insulin and makes people feel full.
The drugs are FDA-approved to help people with type 2 diabetes manage their blood sugar, to help ... |
| 03.06.2024 | Communiqué de presse : ASCO : Sarclisa, en association avec un protocole VRd, est le premier anti-CD38 permettant d’améliorer significativement la survie sans progression des patients […] | ASCO : Sarclisa, en association avec un protocole VRd, est le premier anti-CD38 permettant d’améliorer significativement la survie sans progression des patients atteints d’un myélome multiple nouvellement diagnostiqué, non éligibles à une t... |
| 03.06.2024 | Tagrisso plus chemo recommended for approval in EU | Tagrisso plus chemo recommended for approval in EU
Mon, Jun 03, 2024 08:00 CET Report this content
3 June 2024
Tagrisso with the addition of chemotherapy recommended for approval in
the EU by CHMP for patients with EGFR-mutated advanced lun... |
| 03.06.2024 | Press Release: ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 | ASCO: Sarclisa is first anti-CD38 to significantly improve progression-free survival in combination with VRd for newly diagnosed transplant-ineligible multiple myeloma in phase 3 Sarclisa, in combination with standard-of-care bortezomib, le... |
| 31.05.2024 | Moderna's RSV vaccine for older adults approved | figcaption>span]:font-sans">
Moderna's RSV shot for adults 60 and older was approved by the Food and Drug Administration on Friday, joining a growing group of vaccines protecting against the major respiratory threat.
Why it matte... |
| 31.05.2024 | Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial | Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial
Fri, May 31, 2024 13:30 CET Report this content
Lund, Sweden, 31 May, 2024. Hansa Biopharma AB, (“Hansa” or the “Company”) (Nasdaq Stockholm: HNSA), today announce... |
| 30.05.2024 | Длительный COVID может стать причиной дефицита когнитивных функций, эквивалентного шести баллам IQ | Ученые обнаружили, что длительный COVID может стать причиной нарушения памяти и когнитивных функций, эквивалентных разнице примерно в шесть баллов IQ. Исследование, в котором приняли участие более 140 тыс. человек, показало, что COVID-19 мо... |
| 28.05.2024 | Promising results for… | Research led by Baylor College of Medicine has shown that a new therapy significantly reduces triglyceride levels in individuals with mixed hyperlipidemia – elevations of triglycerides and cholesterol.
The results, published in the latest e... |
| 28.05.2024 | Weekly Ozempic/Wegovy Injections May Lower Kidney Failure Risk, Study Finds | What You Should Know:
– A new study suggests that a weekly treatment with semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, may significantly reduce the risk of kidney failure and other complications in patients with type 2 d... |
| 27.05.2024 | Semaglutide: A Revolutionary Breakthrough in Diabetes and Kidney Disease Treatment | The 61st ERA Congress unveiled a groundbreaking study that has sent shockwaves through the medical community. The study, known as FLOW (Evaluate Renal Function with Semaglutide Once Weekly), has shed light on the remarkable benefits of sema... |
| 27.05.2024 | Человек-машина: краткий обзор достижений и возможностей биоинженерии | Биоинженерия способна компенсировать недостатки человеческого организма. Эта наука уже позволяет ежедневно спасать людей, а в будущем способна вывести человеческое тело на новый уровень. Некоторые же придерживаются мнения о том, что биоинже... |
| 24.05.2024 | 61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreak... | STOCKHOLM, May 24, 2024 /PRNewswire/ -- A pioneering study, presented today at the 61st ERA Congress, has demonstrated that semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mo... |
| 24.05.2024 | Leqembi[®] approved for the treatment of Alzheimer’s disease in South Korea | Leqembi[®] approved for the treatment of Alzheimer’s disease in South Korea
Fri, May 24, 2024 12:55 CET Report this content
Stockholm, Sweden, May 24, 2024 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the Ministry o... |
| 24.05.2024 | 61st ERA Congress: Semaglutide significantly reduces risk of major kidney disease events, cardiovascular outcomes and mortality in patients with type 2 diabetes and chronic kidney disease, groundbreak... | STOCKHOLM, May 24, 2024 /PRNewswire/ -- A pioneering study, presented today at the 61st ERA Congress, has demonstrated that semaglutide significantly reduces the risk of major kidney disease events, cardiovascular outcomes, and all-cause mo... |
| 23.05.2024 | Further CYP-001 GvHD Clinical Data Published in Nature Medicine | Two-year overall survival rate in patients with steroid-resistant acute GvHD was 60%
MELBOURNE, Australia, May 23, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the "Company"), a cl... |
| 20.05.2024 | Reducing sodium, not flavor: The MSG solution | For centuries, salt has played a pivotal role in food – from acting as a preservative to a means to bring out flavor. Today, as our understanding of health and nutrition has grown, we also have expanded awareness of the risks associated wit... |
| 19.05.2024 | US race-neutral lung assessments to have profound effects, study finds | Previous
FILE PHOTO: Clinical lead Doctor Al Story points to an x-ray showing a pair of lungs infected with TB (tuberculosis) during an interview with Reuters on board the mobile X-ray unit screening for TB in Ladbroke Grove in London Janua... |
| 18.05.2024 | Детская деменция: что о ней известно, как она возникает и можно ли ее вылечить | «Детство» и «деменция» — два слова, которые не хочется употреблять вместе. Но только в Австралии около 1,4 тыс. детей и подростков живут с детским слабоумием, которое не поддается лечению. Хотя причины этого заболевания отличаются от деменц... |
| 16.05.2024 | Kira Pharmaceuticals to Present Positive Long-term Results of KP104 in Phase 2 Paroxysmal Nocturnal Hemoglobinuria (PNH) Study at the 2024 European Hematology Association (EHA) Hybrid Congress | CAMBRIDGE, Mass., May 16, 2024 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced that it will present positive long-term ... |
| 16.05.2024 | Dr. Daniel Geynisman Named New Editor-in-Chief for JNCCN--Journal of the National Comprehensive Cancer Network | Chief of the Genitourinary Division for Fox Chase Cancer Center, and Member of two NCCN Guidelines Panels to oversee high-impact oncology research journal.
PLYMOUTH MEETING, Pa., May 16, 2024 /PRNewswire/ -- Daniel M. Geynisman, MD, is bein... |
| 15.05.2024 | Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing | Eisai initiates rolling Biologics License Application to US FDA for Leqembi® (lecanemab-irmb) for subcutaneous maintenance dosing
Wed, May 15, 2024 01:30 CET Report this content
Stockholm, Sweden, May 15, 2024 – BioArctic AB's (publ) (Nasda... |
| 15.05.2024 | Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 – March 2025) | Eisai projects Leqembi® revenue to total JPY 56.5 billion for fiscal year 2024 (April 2024 – March 2025)
Wed, May 15, 2024 05:45 CET Report this content
Stockholm, Sweden, May 15, 2024 – BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) part... |
| 14.05.2024 | Could better inhalers help patients, and the planet? | Patients in the United States are prescribed roughly 144 million of what doctors call metered-dose inhalers each year, according to the most recently available data published in 2020. The cumulative amount of gas released is the equivalent ... |
| 14.05.2024 | CRISPR на практике. Восстанавливая зрение | Буквально на днях публиковал новость о том, что в мир вышла нейросеть, которая предлагает немалый потенциал для развития биотехнологий. И что возможности современной медицины постепенно расширяются. Что ж, мир технологий и правда не стоит н... |
